This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Stephanie Clark
Director, Risk Management - Central Monitoring at The Janssen Pharmaceutical Companies of Johnson & Johnson


Stephanie Clark is a Director in Janssen R&D’s Risk Management-Central Monitoring Group, dedicated to the design and implementation of Analytical Risk-Based Monitoring on clinical trials. In this role, Stephanie has spent the past 7+ years contributing to the creation and management of processes, resources, and technology to support the analytical and risk-based model of clinical trial management and monitoring that has now supported more than 250 clinical studies across multiple sectors at Johnson & Johnson (including Pharma, Medical Devices, and Consumer products). She has also participated as a member of the TransCelerate BioPharma Risk-Based Monitoring Initiative. Stephanie has over 15 years of experience in clinical research and drug development. Prior to her ARBM-focus, she worked in clinical trial and site management at Janssen R&D and Centocor R&D, at RPS, Inc., and at ICON in a variety of therapeutic areas, as well as in basic immunological research at Children’s Hospital of Philadelphia.

Agenda Sessions

  • Panel Debate: State of the Industry from Stakeholders

  • Panel Discussion: Innovative Approaches to Remote Monitoring During and Post - COVID-19